Evicenter
Ubrelvy (ubrogepant) in Acute treatment of migraine
Manufacturer
AbbVie Inc.
Prescribing information
Ubrelvy (opens in a new tab)
Questions
59
Last updated

All questions

Clinical trials: Ubrelvy (ubrogepant) in acute treatment of migraine

6 questions · 3 sources

Study results

How was Ubrelvy studied in its pivotal acute migraine trials?

Note: The label calls the pivotal trials Study 1 and Study 2; the safety page of the Ubrelvy HCP site refers to them as ACHIEVE I and II. The last passage is from the home page of the Ubrelvy HCP site, which cites Dodick et al., Headache 2020.

How many patients were pain free 2 hours after Ubrelvy vs placebo?

Note: Table 3 columns are Study 1 (UBRELVY 50 mg, UBRELVY 100 mg, placebo) followed by Study 2 (UBRELVY 50 mg, placebo), in that order. Each patient treated one migraine attack of moderate to severe pain. The results page of the Ubrelvy HCP site reports the Study 1 result for UBRELVY 100 mg.

Does Ubrelvy relieve the most bothersome migraine symptom at 2 hours vs placebo?

Note: Table 3 columns are Study 1 (UBRELVY 50 mg, UBRELVY 100 mg, placebo) followed by Study 2 (UBRELVY 50 mg, placebo), in that order. Each patient treated one migraine attack of moderate to severe pain. Most bothersome symptom (MBS) freedom at 2 hours was a co-primary endpoint of both studies.

Does Ubrelvy relieve migraine pain at 2 hours vs placebo?

Note: Table 3 columns are Study 1 (UBRELVY 50 mg, UBRELVY 100 mg, placebo) followed by Study 2 (UBRELVY 50 mg, placebo), in that order. Each patient treated one migraine attack of moderate to severe pain.

How many patients stayed pain free 2 to 24 hours after Ubrelvy vs placebo?

Note: Table 3 columns are Study 1 (UBRELVY 50 mg, UBRELVY 100 mg, placebo) followed by Study 2 (UBRELVY 50 mg, placebo), in that order. Each patient treated one migraine attack of moderate to severe pain. The table continues onto the next page of the label, which gives the sustained pain freedom values.

Did patients taking Ubrelvy in the prodrome avoid moderate to severe headache vs placebo?

Note: The prodrome study is described on the results page of the Ubrelvy HCP site, which cites Dodick et al., Lancet 2023. The Ubrelvy Prescribing Information does not describe this study.